Iceman, Wayne has said that he expects to be reimbursed $25,000 USD for each DurAVR used in trials and we know the reimbursement has been approved by Medicare (which provides health insurance for people more than 65 years old here in the US). So 15 EFS patients and 950 pivotal trial patients (that's about the population Edwards is using for it's next gen Sapien trial they are currently running) multiplied by $25,000 with the USD/AUD conversion factor of 0.66 gives $37 million.
And coads, I know Wayne mentioned the FDA and ViV in passing at the AGM but my informed opinion is that it won't happen. Just my opinion based on my experience with companies and the FDA but I could be wrong. In fact I'd love to be wrong but I don't see us getting an exemption to do ViV outside of a relatively small trial setting.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)